| Market Capitalization (Millions $) |
76 |
| Shares
Outstanding (Millions) |
43 |
| Employees |
21 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-20 |
| Cash Flow (TTM) (Millions $) |
10 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Gain Therapeutics Inc. is a biotechnology company that focuses on developing small molecule therapeutics to treat rare genetic diseases and neurodegenerative disorders. The company specializes in developing drugs that target misfolded proteins, which are a common cause of these diseases. Gain Therapeutics utilizes proprietary technology platforms and computational algorithms to identify potential drug candidates and design molecules that can stabilize or restore the function of the misfolded proteins. By addressing the root cause of the diseases, the company aims to provide breakthrough treatments that can significantly improve the lives of patients. Gain Therapeutics is headquartered in Spain and Switzerland, and collaborates with leading academic institutions and research organizations to advance its drug development programs.
Company Address: 4800 Montgomery Lane Bethesda 20814 MD
Company Phone Number: 500-1556 Stock Exchange / Ticker: NASDAQ GANX
|
0.13% 